| The BurnAlong Pilot Study for Adolescent and Young Adult Cancer Survivors (NCT05131815) | Cedars-Sinai Medical Center | 2022-07-25 |
| A Study of DZD8586 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (TAI-SHAN1) (NCT05844956) | Dizal Pharmaceuticals | 2022-06-01 |
| Early Detection of Patients at Risk of Developing Anthracycline Cardiotoxicity With TEP/CT -FDG (NCT04892667) | Assistance Publique - Hôpitaux de Paris | 2022-04-01 |
| Long-Term Follow-up Study (NCT05332054) | Caribou Biosciences, Inc. | 2022-03-16 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NCT05219513) | Hoffmann-La Roche | 2022-02-18 |
| Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells (NCT04911478) | Adicet Therapeutics | 2022-02-14 |
| Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL (NCT05153330) | Biomea Fusion Inc. | 2022-01-24 |
| A Dose Finding Study of CC-96673 in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma (NCT04860466) | Celgene | 2022-01-20 |
| Fitness Assessment in Young Adults Recovered From Lymphoma (NCT05188755) | University Hospital, Clermont-Ferrand | 2022-01-01 |
| Phase Ⅰ Clinical Study of Anti-CD52 Monoclonal Antibody in NHL and T-PLL (NCT05557903) | Lanzhou Institute of Biological Products Co., Ltd | 2021-12-20 |
| Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy (NCT04975555) | University of Alabama at Birmingham | 2021-11-15 |
| Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study (NCT04982471) | Celgene | 2021-11-03 |
| A Phase Ia Clinical Study of QLF31907 Injection in Patients With Advanced Malignant Tumors (NCT05150405) | Qilu Pharmaceutical Co., Ltd. | 2021-10-19 |
| Study of Oral LOXO-338 in Patients With Advanced Blood Cancers (NCT05024045) | Eli Lilly and Company | 2021-09-30 |
| A Study of LP-118 in Patients With Advanced Tumors (NCT05025358) | Guangzhou Lupeng Pharmaceutical Company LTD. | 2021-09-08 |
| Clinical Trial Assessing the Immunogenicity of an Anti-pneumococcal Vaccination Strategy (PCV13+PPV23 Versus PREVENAR20) in Adult Patients Treated for a Lymphoma (NCT04460235) | Poitiers University Hospital | 2021-09-07 |
| NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers (NCT05020678) | Nkarta, Inc. | 2021-08-20 |
| Evaluation of Lymphoma Prognosis and Survivorship in Recently Diagnosed Patients, LEO Study (NCT04996706) | Mayo Clinic | 2021-08-16 |
| CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER) (NCT04637763) | Caribou Biosciences, Inc. | 2021-05-26 |
| Observational Study of People Living With HIV Treated With CD19-directed CAR T Cell (NCT05784415) | AIDS Malignancy Consortium | 2021-05-22 |
| A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia) (NCT04849416) | Eli Lilly and Company | 2021-05-14 |
| A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies (NCT04772989) | Arcus Biosciences, Inc. | 2021-03-19 |
| A Phase 1 Study of ADI-001 in B Cell Malignancies (NCT04735471) | Adicet Therapeutics | 2021-03-04 |
| A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (NCT04657224) | Janssen Research & Development, LLC | 2021-02-25 |
| A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (NCT04434196) | Celgene | 2020-12-21 |
| Anti-CD19 FasT CAR-T Cell Therapy for B Cell NHL (NCT04638270) | Xinqiao Hospital of Chongqing | 2020-11-21 |
| A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (NCT04540796) | Janssen Research & Development, LLC | 2020-11-20 |
| A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL) (NCT04245839) | Celgene | 2020-07-14 |
| A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (NCT04210219) | Janssen Research & Development, LLC | 2020-07-02 |
| CAR-37 T Cells in Hematologic Malignancies (NCT04136275) | Marcela V. Maus, M.D.,Ph.D. | 2020-06-19 |
| A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NCT04231747) | Juno Therapeutics, a Subsidiary of Celgene | 2020-05-21 |
| Observational Trial of Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in CLL/SLL and FL (NCT04342117) | SecuraBio | 2020-04-23 |
| Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL (NCT04030195) | Precision BioSciences, Inc. | 2020-03-24 |
| An Individualized Physical Activity Program in Patients Over 65 Years With Hematologic Malignancies (NCT04052126) | Centre Leon Berard | 2019-11-28 |
| Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of CC-95775 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma (NCT04089527) | Celgene | 2019-10-24 |
| A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NCT04077723) | Hoffmann-La Roche | 2019-08-13 |
| Cost-Effectiveness Study of PEG-rhG-CSF in Prophylactic Treatment of Neutropenia After Chemotherapy in Lymphoma (NCT04083079) | Ruijin Hospital | 2019-08-01 |
| Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma (NCT03921879) | Oncotartis, Inc. | 2019-07-29 |
| CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma (NCT04089215) | Shanghai Ming Ju Biotechnology Co., Ltd. | 2019-06-11 |
| A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL) (NCT03930953) | Celgene | 2019-05-20 |
| A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL) (NCT03772288) | Calithera Biosciences, Inc | 2019-04-03 |
| A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (NCT03900598) | Janssen Research & Development, LLC | 2019-04-03 |
| A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007) (NCT03744676) | Juno Therapeutics, a Subsidiary of Celgene | 2018-11-29 |
| A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas (NCT03575351) | Celgene | 2018-10-23 |
| Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003) (NCT03598608) | Merck Sharp & Dohme LLC | 2018-10-17 |
| A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL) (NCT03743246) | Celgene | 2018-10-17 |
| Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma (NCT03682796) | Triphase Research and Development III Corp. | 2018-10-15 |
| Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006) (NCT03483103) | Juno Therapeutics, a Subsidiary of Celgene | 2018-07-27 |
| Symbenda Post-Marketing Surveillance (PMS) (NCT02434484) | Eisai Korea Inc. | 2018-07-04 |
| Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin Lymphoma (NCT03484702) | Celgene | 2018-06-05 |
| Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression (NCT03480360) | Dartmouth-Hitchcock Medical Center | 2018-03-28 |
| CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies (NCT03448393) | National Cancer Institute (NCI) | 2018-03-26 |
| Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (NCT03297606) | Canadian Cancer Trials Group | 2018-03-23 |
| A Study of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NCT03369964) | Hoffmann-La Roche | 2018-03-14 |
| A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma (NCT03357627) | Calithera Biosciences, Inc | 2018-02-16 |
| Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) (NCT03373019) | Fudan University | 2017-12-21 |
| A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies (NCT03310619) | Celgene | 2017-12-20 |
| Nivolumab With Gemcitabine, Oxaliplatin + Rituximab in r/r Elderly Lymphoma Patients (NCT03366272) | Universität des Saarlandes | 2017-12-05 |
| Diagnostic Assessment of 18F-fluciclovine and 18F-FDG -PET/MRI of Primary Central Nervous System Lymphoma (NCT03188354) | Norwegian University of Science and Technology | 2017-11-01 |
| Study of CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell (NCT03019055) | Medical College of Wisconsin | 2017-10-16 |
| An Observational Study of MabThera Subcutaneous (SC) Safety in Participants With Non-Hodgkin's Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL) (NCT03289182) | Hoffmann-La Roche | 2017-09-15 |
| FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma (NCT01410630) | Jonsson Comprehensive Cancer Center | 2017-09-07 |
| A Study of TAK-659 as a Single Agent in Adult East Asian Participants With Non-Hodgkin Lymphoma (NHL) (NCT03238651) | Calithera Biosciences, Inc | 2017-08-01 |
| A Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's Lymphomas (NCT03220347) | Celgene | 2017-07-24 |
| Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. (NCT03229200) | Pharmacyclics Switzerland GmbH | 2017-05-22 |
| Low Dose Plerixafor Plus G-CSF in Mobilizing Stem Cells for Autologous Peripheral Blood Transplantation (NCT03244930) | Hospital Universitario Dr. Jose E. Gonzalez | 2017-05-10 |
| Prospective Multicenters Clinical Cohort Study of Stratified Treatment of Chinese Children With BL/DLBCL (NCT03958916) | Sun Yat-sen University | 2017-05-05 |
| A Prospective Multicenters Clinical Cohort Study of Stratified Treatment of Chinese Children With LBL (NCT03971318) | Sun Yat-sen University | 2017-05-05 |
| A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma (NCT02954406) | Millennium Pharmaceuticals, Inc. | 2017-03-05 |
| Using Telephone Counselling to Improve Exercise Participation in Hematologic Cancer Survivors (NCT03052777) | University of Alberta | 2017-02-21 |
| Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study (NCT03733249) | Bellicum Pharmaceuticals | 2017-01-01 |
| The Value and Mechanisms for Monocytes Subpopulations in Predicting the Prognosis of Lymphomas (NCT03000738) | Peking Union Medical College Hospital | 2016-12-01 |
| Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine (NCT02996773) | University of Arizona | 2016-11-29 |
| PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia (NCT02996617) | Shandong Provincial Hospital | 2016-11-01 |
| Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma (NCT02867618) | Columbia University | 2016-10-16 |
| A Safety and Efficacy Study of CC-90011 in Participants With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas (NCT02875223) | Celgene | 2016-08-31 |
| Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL (NCT02690545) | UNC Lineberger Comprehensive Cancer Center | 2016-08-26 |
| A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma (NCT02703272) | Janssen Research & Development, LLC | 2016-07-01 |
| Administration of T Lymphocytes for Prevention of Relapse of Lymphomas (NCT02663297) | UNC Lineberger Comprehensive Cancer Center | 2016-06-07 |
| Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma (NCT02613598) | University of Michigan Rogel Cancer Center | 2016-05-12 |
| Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols (NCT02682667) | National Cancer Institute (NCI) | 2016-04-11 |
| BEB Conditioning Regimen for Autologous Stem-cell Transplantation(ASCT) in Non-Hodgkin's Lymphoma (NCT02836639) | Pusan National University Hospital | 2016-02-01 |
| Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL) (NCT02626455) | Bayer | 2016-01-06 |
| Safety and Tolerability of BAY1862864 Injection in Subjects With Relapsed or Refractory CD22-positive Non-Hodgkin's Lymphoma (NCT02581878) | Bayer | 2015-11-20 |
| 131Iodine-Tenatumomab Treatment in Tenascin-C Positive Cancer Patients (NCT02602067) | sigma-tau i.f.r. S.p.A. | 2015-11-01 |
| Safety and Efficacy of Intrathecal Rituximab in 16 Children of Stage Ⅲ、ⅣNon-Hodgkin Lymphoma (NCT06190457) | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 2015-09-30 |
| Phase III Copanlisib in Rituximab-refractory iNHL (NCT02369016) | Bayer | 2015-09-22 |
| A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (NCT02500407) | Genentech, Inc. | 2015-09-15 |
| A Study of CC-122 to Assess the Safety and Tolerability in Japanese Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma (NHL) (NCT02509039) | Celgene | 2015-09-02 |
| GOAL: GA101 Plus Pixantrone for Relapsed Aggressive Lymphoma (NCT02499003) | Johannes Gutenberg University Mainz | 2015-08-14 |
| Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL) (NCT02367040) | Bayer | 2015-08-03 |
| Treatment of CIK for Patients With Refractory Non-Hodgkin Lymphoma (NCT02497898) | The First People's Hospital of Changzhou | 2015-07-01 |
| A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL. (NCT02417285) | Celgene | 2015-05-22 |
| Carfilzomib With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NCT02187133) | University of California, San Francisco | 2015-05-05 |
| A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors (NCT02440685) | Asana BioSciences | 2015-05-01 |
| Japanese Phase Ib/II Copanlisib in Relapsed, Indolent B-cell NHL (NCT02342665) | Bayer | 2015-04-21 |
| BI 695500 vs Rituxan First Line Treatment in Patients With Low Tumor Burden Follicular Lymphoma (NCT02417129) | Boehringer Ingelheim | 2015-04-01 |
| Comparative Effectiveness Analysis of Granulocyte Colony Stimulating Factor Originator Products Versus Biosimilars (NCT04971304) | Catherine M. Lockhart | 2015-03-01 |
| Safety Study of SEA-CD40 in Cancer Patients (NCT02376699) | Seagen Inc. | 2015-02-28 |
| ESHAP-Imatinib for Refractory/Relapsed Non-Hodgkin's Lymphoma (NCT02431403) | Pusan National University Hospital | 2015-02-01 |